ALNY · Alnylam Pharmaceuticals, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-01 | PYOTT DAVID E I |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
1,175 |
| 2026-06-01 | PYOTT DAVID E I |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. |
Common Stock
|
17 |
| 2026-06-01 | PYOTT DAVID E I |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. |
Common Stock
|
3,830 |
| 2026-06-01 | Cravatt Benjamin |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant. |
Stock Option (Right to Buy)
|
4,393 |
| 2026-06-01 | PYOTT DAVID E I |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. This stock option was fully vested and exercisable as of June 3, 2017. |
Stock Option (Right to Buy)
|
3,830 |
| 2026-06-01 | Cravatt Benjamin |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-06-01 | PYOTT DAVID E I |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
1,222 |
| 2026-06-01 | PYOTT DAVID E I |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
921 |
| 2026-06-01 | PYOTT DAVID E I |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
495 |
| 2026-05-20 | Ausiello Dennis A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Stock Option (Right to Buy)
|
1,441 |
| 2026-05-20 | Sigal Charles Elliott |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Common Stock
|
671 |
| 2026-05-20 | SCHULMAN AMY W |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Common Stock
|
838 |
| 2026-05-20 | SCHULMAN AMY W |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Stock Option (Right to Buy)
|
1,802 |
| 2026-05-20 | PYOTT DAVID E I |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Common Stock
|
671 |
| 2026-05-20 | KELLOGG PETER N |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Common Stock
|
671 |
| 2026-05-20 | BRANDICOURT OLIVIER |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Stock Option (Right to Buy)
|
1,441 |
| 2026-05-20 | Reitan Colleen F |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Stock Option (Right to Buy)
|
1,441 |
| 2026-05-20 | Sigal Charles Elliott |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Stock Option (Right to Buy)
|
1,441 |
| 2026-05-20 | Reitan Colleen F |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Common Stock
|
671 |
| 2026-05-20 | Arbuckle Stuart A |
EVP, COO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Stock Option (Right to Buy)
|
1,441 |
| 2026-05-20 | HAMBURG MARGARET A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Stock Option (Right to Buy)
|
1,441 |
| 2026-05-20 | Arbuckle Stuart A |
EVP, COO |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Common Stock
|
671 |
| 2026-05-20 | BRANDICOURT OLIVIER |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Common Stock
|
671 |
| 2026-05-20 | HAMBURG MARGARET A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Common Stock
|
671 |
| 2026-05-20 | PYOTT DAVID E I |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Stock Option (Right to Buy)
|
1,441 |
| 2026-05-20 | Ausiello Dennis A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Common Stock
|
671 |
| 2026-05-20 | KELLOGG PETER N |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Stock Option (Right to Buy)
|
1,441 |
| 2026-05-13 | SCHULMAN AMY W |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options exercised and held by the reporting person were due to expire on June 3, 2026. |
Stock Option (Right to Buy)
|
11,250 |
| 2026-05-13 | SCHULMAN AMY W |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The options exercised and held by the reporting person were due to expire on June 3, 2026. |
Common Stock
|
11,250 |
| 2026-04-06 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.10 to $320.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
56 |
| 2026-04-06 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.21 to $330.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
829 |
| 2026-04-06 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $333.39 to $334.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
199 |
| 2026-04-06 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.22 to $330.18. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
909 |
| 2026-04-06 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.77 to $332.14. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
293 |
| 2026-04-02 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.26 to $322.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
224 |
| 2026-04-02 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.09 to $318.83. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
209 |
| 2026-04-02 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. |
Common Stock
|
8 |
| 2026-04-02 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.21 to $321.11. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
147 |
| 2026-04-02 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $317.07 to $318.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
359 |
| 2026-04-02 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $316.04 to $317.03. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
265 |
| 2026-04-02 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.19 to $320.10. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
86 |
| 2026-04-02 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.31 to $323.13. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
245 |
| 2026-04-02 | McLaughlin Melissa |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.39 to $324.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
81 |
| 2026-03-05 | Garg Pushkal |
EVP Chief R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.26 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
510 |
| 2026-03-05 | Garg Pushkal |
EVP Chief R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.09 to $324.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
740 |
| 2026-03-05 | Fitzgerald Kevin Joseph |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.01 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
153 |
| 2026-03-05 | Fitzgerald Kevin Joseph |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.43 to $322.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
124 |
| 2026-03-05 | Garg Pushkal |
EVP Chief R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.67 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
500 |
| 2026-03-05 | Fitzgerald Kevin Joseph |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.81 to $323.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
233 |
| 2026-03-05 | Garg Pushkal |
EVP Chief R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.03 to $322.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Common Stock
|
654 |